IFB-088 slows disease progression in bulbar-onset ALS trial
Oral therapy IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with amyotrophic lateral sclerosis (ALS),…
Articles by Marisa Wexler, MS
AMT-162 gene therapy trial for SOD1-ALS set for next dose group
uniQure is planning to start enrolling patients in a second dose group as part of a clinical trial testing…
Diabetes, high cholesterol linked with lower risk of developing ALS
People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor…
Feeding tube best placed before major weight loss with ALS: Study
People with amyotrophic lateral sclerosis (ALS) who get a feeding tube placed after losing a lot of weight are…
HEALEY ALS trial to allow longer follow-up, blood cell collection
The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is…
FDA outlines steps to consider accelerated approval of CNM-Au8
The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to…
Brain scans may predict ALS risk in C9ORF72 mutation carriers
People with mutations in the C9ORF72 gene who develop amyotrophic lateral sclerosis (ALS) show signs of damage to certain…
Long-term use of NurOwn shows survival benefit in ALS: New data
Long-term treatment with the cell therapy NurOwn (debamestrocel) was found to significantly extend survival in people with amyotrophic…
Neurosense, FDA to meet on Phase 3 plans for PrimeC in ALS
Neurosense Therapeutics will meet with the U.S. Food and Drug Administration (FDA) Nov. 6 to discuss plans for a Phase…
Radicava ORS slows ALS disease progression, improves survival
Treatment with Radicava ORS (edaravone) significantly slowed declines in physical function and improved survival outcomes for people with…